Addiction to apomorphine: A clinical case-centred discussion

Addiction

Volumn 101, Issue 11, 2006, Pages 1662-1665

  Téllez, Carlos ^a   Bustamante, M Leonor ^a   Toro, Pablo ^a   Venegas, Pablo ^a  

^a HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

Addiction; Anti Parkinsonian drugs; Apomorphine

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LORAZEPAM;

AGED; ALERTNESS; ANXIETY DISORDER; ARTICLE; CASE REPORT; DRUG DEPENDENCE; DRUG INDICATION; ERECTILE DYSFUNCTION; FEMALE; HUMAN; HYPERSEXUALITY; HYPOMANIA; INSOMNIA; MENTAL DISEASE; MOOD DISORDER; PARKINSON DISEASE; PRESCRIPTION; PREVALENCE; SELF CONTROL; SENSATION; WAKEFULNESS;

ANTIPARKINSON AGENTS; APOMORPHINE; DOPAMINE AGONISTS; FEMALE; HUMANS; MIDDLE AGED; MORPHINE DEPENDENCE; PARKINSON DISEASE;

EID: 33749509247     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2006.01580.x     Document Type: Article

References (24)

1. Courty E., Durif F., Zenut M., Courty P., Lavarenne J. Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease. Clin Neuropharmacol 1997; 20: 140-7.
2. Bett W. R. John Yerbury Dent. Br J Addict 1962; 58: 2-4.
3. Dent J. Y. Apomophine treatment of addiction. Br J Addict 1949; 46: 15-28.
4. Dent J. Y. Apomorphine in the treatment of addiction to 'other drugs'. Br J Addict 1953; 50: 43-5.
5. Burroughs W. Letter from a master addict to dangerous drugs. Br J Addict 1957; 53: 119-31.
6. Burroughs W. Naked Lunch . New York: Grove Press, 1992.
7. Argiolas A., Hedlund H. The pharmacology and clinical pharmacokinetics of apomorphine SL. BJU Int 2001; 88: 18-21.
8. Lal S. Apomorphine in the evaluation of dopaminergic function in man. Prog Neuro-psychopharmacol Biol Psychiatry 1998; 12: 117-84.
9. Deleu D., Hanssens Y., Northway M. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004; 21: 687-709.
10. Ehringer H., Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidales System [Distribution of noradrenaline and dopamine in the brain of man and its behaviour in extrapiramidal system diseases]. Klin Wochenschr 1960; 38: 1236-9.
11. Ring H., Mestres-Serra J. Neuropsychiatry of the basal ganglia. J Neurol Neurosurg Psychiatry 2002; 72: 12-21.
12. Jenner P. Dopamine agonists: receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol 2003; 16: S3-7.
13. Miranda M., Villagra R. Apomorfina subcutánea en la Enfermedad de Parkinson [Subcutaneous Apomorphine in Parkinson's Disease]. Rev Méd Chile 1996; 124: 1398-9.
14. Morgante L., Basile G., Epifanio A., Spina E., Antonini A., Stochi F. et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. Arch Gerontol Geriatr 2004; Suppl. 9: 291-296.
15. American Psychiatry Association. Diagnostic and Statistic Manual of Mental Disorders ,4th edn, text revision. Washington, DC: American Psychiatric Association; 2000.
16. Nestler E. Is there a common molecular pathway for addiction? Nat Neurosci 2005; 8: 1445-9.
17. Isella V., Iurlaro S., Piolti R., Ferrarese C., Frattola L., Appollonio I. Physical anhedonia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74: 1308-11.
18. Burn D. Depression in Parkinson's disease. Eur J Neurol 2002; 9(Suppl. 3): 44-54.
19. Sacks O. Awakenings . Kent: Picador; 1999, p. 9.
20. Cantello R. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 69: 566-7.
21. Tack E., De Cuypere G., Jannes C., Remouchamps A. Levodopa addiction. A case study. Acta Psychiatr Scand 1988; 78: 356-60.
22. Giovannoni G., O'Sullivan J., Turner K., Manson A., Lees A. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68: 423-8.
23. Pezzella F., Colosimo C., Vanacore N., Di Rezze S., Chianese M., Fabbrini G. et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 2005; 1: 77-81.
24. Lawrence A., Evans A., Lees A. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003; 2: 595-604.